Floatz logo

Rso-021

Pleural Effusion, Malignant

RS Oncology LLCPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Pleural Effusion, Malignant cohort.

Asset / SponsorPhaseRating
Zoledronate
Novartis Pharmaceuticals
Phase 4BB
Nivolumab
Kidney Cancer Research Bureau
Phase 2B
Docetaxel
Asan Medical Center
Phase 2B
(+)-VINCRISTINE
Institut Curie
Phase 1CC
Irinotecan
Institut Curie
Phase 1CC

View all 9 →

Same molecule, other indications

Rso-021 is also rated in:

pleural neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
malignant pleural mesotheliomaDormant
CCC
Indicative ·
48 / 100
View asset →
pleural mesotheliomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →